Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

J. K. Overbeek, R. ter Heine, H. M.W. Verheul, E. Chatelut, M. A. Rudek, H. Gurney, R. Plummer, D. C. Gilbert, T. Buclin, D. M. Burger, H. J. Bloemendal, N. P. van Erp*

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

2 Downloads (Pure)
Original languageEnglish
Article number100749
JournalESMO Open
Issue number1
Publication statusPublished - Feb 2023

Bibliographical note

Funding Information:
This work was supported by ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program [grant 10140021910005 ]. MAR was supported by NCI grants UM1CA186691 , U24CA247648 , and P30CA006973 .

Cite this